베타
임상 레이더 AI
임상시험 NCT07494526은(는) Chronic Kidney Diease, 당뇨병, 고혈압, 고지혈증, 고요산혈증에 대해 대상자모집전 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요.
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰

Chronic Kidney Disease and Metabolic Disorders in the Elderly 100,000 고령자 관찰 연구

대상자모집전
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '임상시험 설명'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT07494526은(는) Chronic Kidney Diease, 당뇨병, 고혈압, 고지혈증, 고요산혈증에 대해 알아보는 관찰연구입니다. 현재 상태는 대상자모집전이며, 2026년 4월 1일부터 참여 신청이 가능합니다. 100,000명의 참여자를 모집할 예정입니다. Chinese PLA General Hospital이(가) 진행하는 이 연구는 2028년 12월 1일까지 진행될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2026년 3월 27일에 갱신되었습니다.
간단한 개요
The goal of this observational study is to investigate the impact of metabolic comorbidities on outcomes in elderly Chinese adults, through two parallel sub-cohorts: one comprising elderly individuals without chronic kidney disease (CKD) at baseline, and one comprising elderly patients with established CKD.

The main questions it aims to answer are:

Do metabolic diseases (diabetes, hypertension, hyperlipidemia, hype...

더 보기
상세한 설명
Background and Rationale Chronic kidney disease (CKD) complicated by metabolic disorders - including diabetes mellitus, hypertension, hyperlipidemia, hyperuricemia, and calcium-phosphorus disturbances - poses a significant public health threat to the elderly population. China is experiencing accelerating demographic aging, making the burden of CKD and metabolic comorbidity in older adults an increasingly pressing cli...더 보기
공식 제목

Research on the Prevention, Control, and Intelligent Management Decision-Making for Comorbidities of Chronic Kidney Disease and Metabolic Disorders in the Elderly

질환명
Chronic Kidney Diease당뇨병고혈압고지혈증고요산혈증
출판물
이 임상시험에 대해 발표된 과학 논문 및 연구 자료.
기타 연구 식별자
  • 2024YFC3607400
  • 2024YFC3607400 (기타 보조금/자금 번호) (National Key Research and Development Program of China)
NCT 번호
실제 연구 시작일
2026-04
최신 업데이트 게시
2026-03-27
예상 연구 완료일
2028-12
계획된 등록 인원
100,000
연구종류
관찰연구
상태
대상자모집전
키워드
chronic kidney disease
elderly
metabolic disorders
시험군 / 개입
참가자 그룹/시험군개입/치료
Sub-cohort 1 - Elderly Adults without chronic kidney disease (CKD) at Baseline
해당 없음
Sub-cohort 2 - Elderly Patients with chronic kidney disease (CKD)
해당 없음
주요결과변수
결과변수측정값 설명시간 범위
incident CKD
For Sub-cohort 1 in Elderly Adults without CKD at Baseline, the primary outcome is incident CKD, which is defined as glomerular filtration rate (eGFR) \< 60 ml/(min·1.73m²) or positive urine protein; or the presence of a clear ICD-10 diagnostic code for CKD in medical records.
through study completion, an average of 1 year
All-cause mortality
From date of enrollment until death from any cause, assessed up to 5 years
Progression to ESRD.
From date of enrollment until progression to ESRD or death from any cause, whichever came first, assessed up to 5 years
참여 도우미
적격성 기준

연령대
노인
최소 연령
65 Years
참여 가능한 성별
전체
건강한 참가자 허용
EXCLUSION CRITERIA:

INCLUSION CRITERIA:

  1. Baseline age ≥ 65 years.
  2. Availability of baseline data on serum creatinine and at least one urinary protein measurement.
  3. Urinary protein measurements include: UACR, UPCR, 24-hour urine protein quantification, and urine protein dipstick test.
  4. Baseline date requirement: Between January 1, 2010, and December 31, 2025.
  5. Follow-up requirement meeting at least one of the following: At least one serum creatinine measurement with an interval of ≥ 6 months after baseline. Occurrence of a primary endpoint event (new-onset CKD).

Exclusion Criteria:

Presence of CKD at baseline, defined as: Glomerular filtration rate (eGFR) < 60 ml/(min·1.73m²) or positive urine protein; or the presence of an ICD-10 diagnostic code for CKD in medical records.

For Sub-cohort 2 (CKD Patients), the inclusion and exclusion criteria are as follows:

Inclusion Criteria:

  1. Baseline age ≥ 65 years.
  2. Meeting the diagnostic criteria for CKD: Glomerular filtration rate (eGFR) < 60 ml/(min·1.73m²) or urine protein (UACR ≥ 30 mg/g); or based on ICD-10 codes.
  3. Baseline date requirement: Between January 1, 2010, and December 31, 2025.
  4. Follow-up requirement meeting at least one of the following:

Occurrence of a primary endpoint event (mortality, ESRD); At least one serum creatinine measurement with an interval of ≥ 6 months after baseline.

Exclusion Criteria:

  1. End-stage renal disease (ESRD) at baseline (eGFR < 15 ml/(min·1.73m²), or prior receipt of kidney transplant or dialysis), based on ICD codes).
  2. Diagnosis of acute kidney injury (AKI) within the preceding 3 months.
  3. New York Heart Association (NYHA) Class III or IV heart failure or occurrence of acute myocardial infarction within the preceding 6 months.
  4. Child-Pugh Class B or C liver cirrhosis.
  5. Malignant neoplasm.
Chinese PLA General Hospital logoChinese PLA General Hospital
연구 책임자
Yuanjun Yang, 책임연구자, Principal Investigator, Chinese PLA General Hospital
연구 대표 연락처
연락처: Shuang Liang, 86+15110246423, [email protected]
2 1개국에 임상시험 장소

Beijing Municipality

Chinese PLA General Hospital, Beijing, Beijing Municipality, 100853, China
chinese PLA general hospital, Beijing, Beijing Municipality, 100853, China
Shuang Liang, PhD, 연락처, 86+15110246423, [email protected]
Yisha Li, PhD, 연락처, 86+18911772124, [email protected]